Citadel Advisors
EWTX icon

Citadel Advisors’s Edgewise Therapeutics EWTX Stock Holding History

Citadel Advisors’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.26M Buy
55,700
+45,600
+451% +$1.57M ﹤0.01% 6282
2026
Q1 		$318K Sell
10,100
-63,400
-86% -$1.83M ﹤0.01% 10342
2025
Q4 		$1.82M Buy
73,500
+27,400
+59% +$550K ﹤0.01% 6113
2025
Q3 		$748K Buy
46,100
+8,100
+21% +$115K ﹤0.01% 8187
2025
Q2 		$498K Sell
38,000
-12,600
-25% -$182K ﹤0.01% 8644
2025
Q1 		$1.11M Buy
50,600
+10,400
+26% +$273K ﹤0.01% 6725
2024
Q4 		$1.07M Sell
40,200
-29,800
-43% -$949K ﹤0.01% 6861
2024
Q3 		$1.87M Buy
70,000
+59,100
+542% +$1.18M ﹤0.01% 5666
2024
Q2 		$196K Sell
10,900
-3,800
-26% -$66.3K ﹤0.01% 9973
2024
Q1 		$268K Buy
14,700
+10,100
+220% +$161K ﹤0.01% 9716
2023
Q4 		$50.3K Buy
4,600
+3,500
+318% +$24.6K ﹤0.01% 11777
2023
Q3 		$6.3K Buy
1,100
+100
+10% +$680 ﹤0.01% 13325
2023
Q2 		$7.75K Sell
1,000
-600
-38% -$5.06K ﹤0.01% 13356
2023
Q1 		$10.7K Sell
1,600
-1,200
-43% -$11.1K ﹤0.01% 13514
2022
Q4 		$25K Buy
+2,800
New +$26.3K ﹤0.01% 12942

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors's EWTX Position: Q2 2026 in Review

Citadel Advisors increased its Edgewise Therapeutics (EWTX) stake by 9.5% in Q2 2026, buying an estimated $1.4M and bringing the position to 469,707 shares worth $19.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2652.

Citadel Advisors first reported a position in EWTX in Q1 2021 and has held it in 22 quarters since. The position peaked at $77.4M in Q1 2021. 226 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Citadel Advisors held 469,707 shares of Edgewise Therapeutics worth $19.1M as of Q2 2026.
  • Citadel Advisors bought 40,675 Edgewise Therapeutics shares in Q2 2026, an estimated $1.4M.
  • Edgewise Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #2652 holding.
  • Citadel Advisors first reported a position in Edgewise Therapeutics in Q1 2021 and has held it in 22 quarters since.
  • Citadel Advisors's Edgewise Therapeutics position peaked at $77.4M in Q1 2021.
  • 226 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.